Interview with Richard Blackburn, Managing Director, Pfizer UK
As part of a panel discussion with Claudia Hammond of the BBC last year, you commented on the fairly poor relationship between the NHS and industry, and the need to…
Address: 4th Floor 44-46 Whitfield Street London W1T 2RJ,United Kingdom
Tel: +44 (0) 20 7388 7722
Web: http://www.arktherapeutics.com/main/index.php?content=home_page
Ark Therapeutics Group plc is an innovative gene-based medicine company with operations in the UK and Finland. Ark seeks to capitalize on its pipeline of programs in high value areas of unmet medical need within vascular disease and cancer Ark has also developed a small molecule platform based on its acknowledged leadership in vascular biology and is currently working on an exciting NRP-1 antagonist program which is already the subject of interest from major pharmaceutical companies.
Ark is distinguished by:
• Development products addressing clear, unmet needs
• Highly valuable GMP manufacturing expertise, characterized by a proven expertise in chemistry and manufacturing control and development of biological in approved facilities.
• Broad follow-on preclinical portfolio – Ark’s founding scientists have acknowledged world-renowned expertise in vascular biology and molecular medicine.
As part of a panel discussion with Claudia Hammond of the BBC last year, you commented on the fairly poor relationship between the NHS and industry, and the need to…
Together with Germany, the UK the highest generic penetration rate in Europe. Since you have been with the association since 1995 and obviously saw the great emergence of the generic…
What are the priorities on your agenda as the new head of ABPI considering the successes and difficulties the association has experienced in the past? If you look at the…
The UK has got around half of the public biotech companies and 21% of all entrepreneurial bioscience companies in Europe. From your perspective, can you explain what the key success…
AstraZeneca reported decrease in its global revenue for the first half of 2011 mostly due to adverse market conditions in the US. In this context, how has the company been…
Thank you for having us today! You have been chief executive of the Association since 1990 and obviously observed the evolution of the OTC market from close by. From your…
Given the heated debate over NHS reform and the new revised bill proposed by the government, what are you current priorities as President of the ABPI and how have these…
See our Cookie Privacy Policy Here
